Disruptive Pharma AB
Peter Åsberg is a seasoned executive in the pharmaceutical industry, currently serving as CEO of Disruptive Pharma AB since June 2021, where the focus is on innovative drug delivery technologies. Prior roles include Senior Vice President and Director of Business Unit Pharma at Disruptive Materials AB, and CEO positions at Olink Bioscience and BioChromix Pharma AB, demonstrating a strong background in drug development and commercialization. Peter Åsberg has also contributed to patient safety initiatives as Regional Business Development Director at Aegate and has a solid foundation in research from Linköping University, where a PhD in Biomolecular and Organic Electronics was obtained. Education includes an MSc from Stanford University and an engineering degree from Linköping University, highlighting expertise in both scientific and engineering principles within the life sciences.
This person is not in the org chart
This person is not in any teams
Disruptive Pharma AB
Disruptive Pharma is a pharmaceutical company that develops novel drug products by applying a unique drug delivery technology. We develop selected drug products based on our proprietary drug delivery platform, the pharma-grade mesoporous magnesium carbonate (Pharma-MMC). The Disruptive Pharma company has offices in both Uppsala (HQ) and Stockholm. By a clever combination of already approved active pharmaceutical ingredients (APIs) with Pharma-MMC platform, several unique opportunities to realize highly valuable therapeutically equivalent or improved drug products emerges. The Pharma-MMC drug delivery technology can be used to create amorphous solid dispersions of the drug, hence increasing its dissolution and the body’s ability to absorb the drug, and may be used to rescue particularly difficult drugs or to enable novel product formulations Disruptive Pharma is a spin-out from the company Disruptive Materials that is located in Uppsala. The company is well-positioned to exploit its pioneering discovery of a unique mesoporous magnesium carbonate (MMC) material. Up until breakthrough discovery by the group of Professor Maria Strømme in 2012, commercialized by Disruptive Materials AB in 2013.